GSK3B and Alzheimer disease: Our analysis seeks to understand the relationship between the chemical structures of GSK-3β inhibitors and their activity within the context of AD, utilizing a systems pharmacology framework and quantitative structure–activity relationship (QSAR) modeling, a technique used to discover connections between chemical compounds’ biological activities and their structural properties [18,19].